CHMP recommends Somatropin Biopartners for Growth Hormone Deficiency
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion regarding the approval of once-weekly Somatropin Biopartners from Biopartners for the treatment of Growth Hormone Deficiency (GHD) in paediatric and adult patients.
Somatropin Biopartners is the first prolonged-release somatropin-containing medicinal product to receive a positive CHMP opinion. Somatropin Biopartners will allow for a once-weekly subcutaneous injection instead of the currently available therapies that require once-daily injections of growth hormone (GH). Poor adherence and noncompliance have been identified as a major cause of suboptimal efficacy of current GH replacement therapy in children as well as adults.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins